Please use this identifier to cite or link to this item: http://earsiv.odu.edu.tr:8080/xmlui/handle/11489/4544
Title: Use of TIMI Risk Index as a Simple and Valuable Prognostic Tool in Patients with ST-Segment Elevation Myocardial Infarction Who Underwent Primary Percutaneous Coronary Intervention
Authors: Cerik, Idris Bugra
Kaya, Ahmet
Dereli, Seckin
Akkaya, Fatih
Yenercag, Mustafa
Bektas, Osman
Ordu Üniversitesi
0000-0001-9845-7938
0000-0003-0090-3835
0000-0002-0933-7852
0000-0003-1419-3950
Keywords: TIMI risk index, ST-elevation myocardial infarction, prognosis
NO-REFLOW PHENOMENON, THROMBOLYSIS, MORTALITY, ADMISSION, GUIDELINES, MANAGEMENT, OUTCOMES, REGISTRY, SOCIETY, SCORE
Issue Date: 2022
Publisher: AVES-SISLI
Citation: Çerik, IB., Kaya, A., Dereli, S., Akkaya, F., Yenerçag, M., Bektas, O. (2022). Use of TIMI Risk Index as a Simple and Valuable Prognostic Tool in Patients with ST-Segment Elevation Myocardial Infarction Who Underwent Primary Percutaneous Coronary Intervention. Turk Kardiyol. Dern. Ars., 50(3), 192-201. https://doi.org/10.5543/tkda.2022.21143
Abstract: Objective: Thrombolysis in Myocardial Infarction Risk Index is a risk stratification model developed to determine the prognosis in ST-segment elevation myocardial infarction patients who underwent fibrinolytic therapy. The information on the effectiveness of Thrombolysis in Myocardial Infarction Risk Index in patients who underwent primary percutaneous coronary intervention is limited. This study aimed to demonstrate the predictive value of Thrombolysis in Myocardial Infarction Risk Index on clinical outcomes in patients presenting with ST-segment elevation myocardial infarction and subsequently undergoing primary percutaneous coronary intervention. Methods: A total of 963 patients who presented with ST-segment elevation myocardial infarction and subsequently underwent primary percutaneous coronary intervention were reviewed retrospectively. The discriminative power of Thrombolysis in Myocardial Infarction Risk Index for each outcome of congestive heart failure, death, stroke, and myocardial infarction within 1 month and 1 year after admission was assessed. Results: Congestive heart failure, death, stroke, and myocardial infarction, and the major adverse cardiac events, which is the composite outcome thereof, were higher in the patient groups with high Thrombolysis in Myocardial Infarction Risk Index values (P<.05). Thrombolysis in Myocardial Infarction Risk Index was an independent predictor of the following outcomes: 1-month survival rate [odds ratio:1.054 (1.036-1.073)], 1-year survival rate [odds ratio:1.048 (1.031-1.065)], hospitalization rate due to congestive heart failure within 1 month [odds ratio:1.041(1.026-1.057)], and within 1 year [odds ratio:1.040 (1.024-1.055)]. The Thrombolysis in Myocardial Infarction Risk Index level was found to have good discriminative power for 1-month mortality and 1-year mortality rates (Thrombolysis in Myocardial Infarction Risk Index: 22.76, C-statistic: 0.71-0.68, respectively). Conclusion: The results of this study indicated that Thrombolysis in Myocardial Infarction Risk Index value is an independent predictor of clinical outcomes such as death and heart failure but not subsequent myocardial infarction in ST-segment elevation myocardial infarction patients. The use of Thrombolysis in Myocardial Infarction Risk Index can be considered in ST-segment elevation myocardial infarction patients who underwent primary percutaneous coronary intervention as it is an easily applicable and important indicator of prognosis.
Description: WoS Categories: Cardiac & Cardiovascular Systems
Web of Science Index: Emerging Sources Citation Index (ESCI)
Research Areas: Cardiovascular System & Cardiology
URI: http://dx.doi.org/10.5543/tkda.2022.21143
https://www.webofscience.com/wos/woscc/full-record/WOS:000867820700005
http://earsiv.odu.edu.tr:8080/xmlui/handle/11489/4544
ISSN: 1016-5169
Appears in Collections:Dahili Tıp Bilimleri

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.